REHOVOT, Israel, February 3, 2014 /PRNewswire/ --
Advanced Inhalation Therapies (AIT), a leader in the development of nitric oxide (NO) therapeutics for the treatment of infectious respiratory diseases announced today that its lead investigator will present clincial trial results at the upcoming 2014 Israeli clinical Pediatric Society - The Annual Meeting of the Israeli Association of Clinical Pediatrics in Tel-Aviv, Israel, February 5, 2014.
The presentation entitled "Prospective, double-blind, randomized controlled trial, evaluation of the safety and tolerability of intermittent high-dose inhaled nitric oxide in infants with acute bronchiolitis," will be given by Professor Asher Tal, M.D., the principal investigator of the trial. Professor Tal is a professor of pediatrics and Head of the Department of Pediatrics B at Soroka University Medical Center, Israel.
As part of the presentation, Professor Tal will review the Company's Phase II clinical trail results for acute bronchiolitis.
AIT's presentation is scheduled for Wednesday, Faburary 5, 2014, at 1:50 PM and will be part of the 'Pulmonary medicine and critical care' session that will take place in auditorium B.
About Nitric Oxide
Nitric oxide is a small, unstable, naturally produced gas that acts as an anti-infection agent, efficient in treating a wide range of diseases. AIT uses nitric oxide in unique dosages and modes of delivery to enable direct, effective access to the lungs.
AIT (http://www.ait-pharm.com) is a drug development company focused on the development and commercialization of nitric oxide formulations for the treatment of infectious respiratory diseases such as bronchiolitis, cystic fibrosis, pneumonia, and asthma. The Company was founded by Mor Research Applications, a subsidiary of Clalit Health Services, Israel's largest health management organization. AIT is currently recruiting cystic fibrosis patients for Phase II trials.
Racheli Vizman, COO, AIT
2 Derech Meir Weisgal
Rehovot 9632605, Israel
SOURCE Advanced Inhalation Therapies (AIT)